Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 3, 2006, Pages 435-441

  Wickline, Samuel A ^a,b,d   Neubauer, Anne M ^b   Winter, Patrick ^a   Caruthers, Shelton ^c   Lanza, Gregory ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^c PHILIPS HEALTHCARE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast agents; Drug therapy; Imaging; Nanotechnology

Indexed keywords

QUANTUM DOT;

ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DIAGNOSTIC PROCEDURE; HUMAN; INTRAVASCULAR ULTRASOUND; MESENCHYMAL STEM CELL; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGE DISPLAY; PRIORITY JOURNAL; REPRODUCIBILITY; SHORT SURVEY; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; THROMBOSIS;

EID: 33646537848     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000201069.47550.8b     Document Type: Short Survey

References (65)

1. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: state of the science. J Nucl Med. 2003;44:1945-1961.
2. Tsien RY. Imagining imaging's future. Nat Rev Mol Cell Biol. 2003; (suppl):SS16-SS21.
3. Lanza G, Wickline S. Targeted ultrasonic contrast agents for molecular imaging and therapy. Prog Cardiovasc Dis. 2001;44:13-31.
4. Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr Prob Cardiol. 2003;28:625-653.
5. Wickline SA, Lanza GM. Molecular imaging, targeted therapeutics, and nanoscience. J Cell Biochem. 2002;39:90-97.
6. Wickline SA, Lanza GM. Nanotechnology for molecular imaging and targeted therapy. Circulation. 2003;107:1092-1095.
7. 19F nanoparticles. Magn Reson Med. 2004;52:1255-1262.
8. Buxton DB, Lee SC, Wickline SA, Ferrari M, for the Working Group Members. Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation. 2003;108:2737-2742.
9. Demos SM, Alkan-Onyuksel H, Kane BJ, Ramani K, Nagaraj A, Greene R, Klegerman M, McPherson DD. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J Am Coll Cardiol. 1999;33:867-875.
10. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nature Medicine. 1998;4:623-626.
11. Lanza GM, Winter P, Caruthers S, Schmeider A, Crowder K, Morawski A, Zhang H, Scott MJ, Wickline SA. Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. Curr Pharm Biotechnol. 2004;5:495-507.
12. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation. 2001;104:1280-1285.
13. Deleted in proof.
14. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004;126:16316-16317.
15. Li H, Gray BD, Corbin I, Lebherz C, Choi H, Lund-Katz S, Wilson JM, Glickson JD, Zhou R. MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol. 2004;11:1251-1259.
16. Hawker CJ, Wooley KL. The convergence of synthetic organic and polymer chemistries. Science. 2005;309:1200-1205.
17. Kobayashi H, Kawamoto S, Jo SK, Bryant HL Jr, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem. 2003;14:388-394.
18. Sato N, Kobayashi H, Hiraga A, Saga T, Togashi K, Konishi J, Brechbiel MW. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn Reson Med. 2001;46:1169-1173.
19. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, Semmler W, Wolf KJ. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol. 2000;35:460-471.
20. Koch AM, Reynolds F, Merkle HP, Weissleder R, Josephson L. Transport of surface-modified nanoparticles through cell monolayers. Chembiochem. 2005;6:337-345.
21. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A. 2003;100:13549-13554.
22. Loo C, Lin A, Hirsch L, Lee MH, Barton J, Halas N, West J, Drezek R. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat. 2004;3:33-40.
23. Cherukuri P, Bachilo SM, Litovsky SH, Weisman RB. Near-infrared fluorescence microscopy of single-walled carbon nanotubes in phagocytic cells. J Am Chem Soc. 2004;126:15638-15639.
24. Barone PW, Baik S, Heller DA, Strano MS. Near-infrared optical sensors based on single-walled carbon nanotubes. Nat Mater. 2005;4:86-92.
25. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A. 2002;99:12617-12621.
26. Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasqualini R. Design and validation of a bifunctional ligand display system for receptor targeting. Chem Biol. 2004;11:1081-1091.
27. Gao X, Nie S. Quantum dot-encoded beads. Methods Mol Biol. 2005;303:61-71.
28. Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Sheehan CK, Abendschein DR, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation. 1996;95:3334-3340.
29. Lanza GM, Abendschein DR, Hall CS, Scott MJ, Scherrer DE, Houseman A, Miller JG, Wickline SA. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. J Am Soc Echocardiogr. 2000;13:608-614.
30. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Fuhrhop RJ, Scherer DE, Wickline SA. Targeted antiproliferative drug delivery to vascular smooth muscle cells with an MRI nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation. 2002;106:2842-2847.
31. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation. 1997;96:646-652.
32. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM, Wickline SA. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magnc Reson Med. 2004;51:480-486.
33. Hamilton A, Huang SL, Warnick D, Stein A, Rabbat M, Madhav T, Kane B, Nagaraj A, Klegerman M, MacDonald R, McPherson D. Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model. Circulation. 2002;105:2772-2778.
34. Hamilton AJ, Huang SL, Warnick D, Rabbat M, Kane B, Nagaraj A, Klegerman M, McPherson DD. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol. 2004;43:453-460.
35. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005;96:327-336.
36. Lanza GM, Trousil RL, Wallace KD, Rose JH, Hall CS, Scott MJ, Miller JG, Eisenberg PR, Gaffney PJ, Wickline SA. In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J Acoust Soc Am. 1998;104:3665-3672.
37. Botnar RM, Buecker A, Wiethoff AJ, Parsons EC Jr, Katoh M, Katsimaglis G, Weisskoff RM, Lauffer RB, Graham PB, Gunther RW, Manning WJ, Spuentrup E. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110:1463-1466.
38. Spuentrup E, Fausten B, Kinzel S, Wiethoff AJ, Botnar RM, Graham PB, Haller S, Katoh M, Parsons EC Jr, Manning WJ, Busch T, Gunther RW, Buecker A. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation. 2005;112:396-399.
39. Kerr JS, Mousa SA, Slee AM. Alpha(v)beta(3) integrin in angiogenesis and restenosis. Drug News Perspect. 2001;14:143-150.
40. Bishop GG, McPherson JA, Sanders JM, Hesselbacher SE, Feldman MJ, McNamara CA, Gimple LW, Powers ER, Mousa SA, Sarembock IJ. Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation. 2001;103:1906-1911.
41. Corjay MH, Diamond SM, Schlingmann KL, Gibbs SK, Stoltenborg JK, Racanelli AL. Alphavbeta3, alphavbeta5, and osteopontin are coordinately upregulated at early time points in a rabbit model of neointima formation. J Cell Biochem. 1999;75:492-504.
42. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815-1822.
43. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza CM, Wickline SA, Kotyk JJ. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med. 2000;44:433-439.
44. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003;63:5838-5843.
45. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang HY, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta(3)-Integrin- targeted nanoparticles. Circulation. 2003;108:2270-2274.
46. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotien E-defficient mice. Circulation. 1999;99:1726-1732.
47. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J. 1998;135:10-14.
48. Wilson SH, Hermann J, Lermann LO, Holmes DR Jr, Napoli C, Ritman EL, Lerman A. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation. 2002;105:415-418.
49. Zhang Y, Cliff WJ, Schoefl GI, Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol. 1993;143:164-172.
50. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103:415-422.
51. Corot C, Petry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas J-F, Blezer E, Rausch M, Brochet B, Foster-Gareau P, Baleriaux D, Gaillard S, Dousset V. Macrophage imaging in central nervous system and in carotid atheroscerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol. 2004;39:619-625.
52. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453-2458.
53. Trivedi RA, U-King-Im JM, Graves MJ, Cross JJ, Horsley J, Goddard MJ, Skepper JN, Quartey G, Warburton E, Joubert I, Wang L, Kirkpatrick PJ, Brown J, Gillard J. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35:1631-1635.
54. Sirol M, Itskovich VV, Mani V, Aguinaldo JG, Fallon JT, Misselwitz B, Weinmann HJ, Fuster V, Toussaint JF, Fayad ZA. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation. 2004;109:2890-2896.
55. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation. 2003;76:1123-1130.
56. Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, Bryant LH Jr, Bulte JW. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003;228:480-487.
57. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging. 2004;22:843-850.
58. Bulte JW, Kraitchman DL. Monitoring cell therapy using iron oxide MR contrast agents. Curr Pharm Biotechnol. 2004;5:567-584.
59. Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin BJ, Pittenger MF, Hare JM, Bulte JW. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation. 2003;107:2290-2293.
60. de Vries IJM, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJG, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JWM, Scheenen TWJ, Punt CJA, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotech. 2005;23:1407-1413.
61. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23:983-987.
62. Winter PM, Morawski AM, Caruthers SD, Harris TD, Fuhrhop RW, Zhang HY, Allen JS, Lacy EK, Williams TA, Wickline SA, Lanza GM. Antiangiogenic therapy of early atherosclerosis with paramagnetic alpha(v)beta(3)-integrin-targeted fumagillin nanoparticles. J Am Coll Cardiol. 2004;43:322A-323A.
63. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E, Desai N, Soon-Shiong P, Virmani R. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation. 2002;106:1195-1198.
64. Crowder KC, Hughes MS, Marsh JN, Scott MJ, Fuhrhop RW, Lanza GM, Wickline SA. Augmented and selective delivery of liquid perfluorocarbon nanoparticles to melanoma cells with noncavitational ultrasound. Presented at the 2003 IEEE Symposium on Ultrasonics, Honolulu, Hawaii, 2003.
65. Crowder KC, Hughes MS, Marsh JN, Barbieri AM, Fuhrhop R, Lanza GM, Wickline SA. Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery. Ultrasound Med Biol. 2005;31:1693-1700.